| |
|
HCC | Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
|
|
| |
| 2. | Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference |
| |
Clin Gastroenterol Hepatol. 2023 Apr 20;S1542-3565(23)00237-9.doi: 10.1016/j.cgh.2023.03.029. Online ahead of print.
Hashem B El-Serag 1, John W Ward 2, Sumeet K Asrani 3, Amit G Singal 4, Nicole Rich 4, Aaron P Thrift 5, Salil Deshpande 6, Barbara J Turner 7, Ahmed O Kaseb 8, Ariel C Harrison 9, Brett E Fortune 10, Fasiha Kanwal 9
|
|
| |
|
|
| |
| 4. | Risk factors for HCC in contemporary cohorts of patients with cirrhosis |
| |
Hepatology. 2023 Mar 1;77(3):997-1005. doi: 10.1002/hep.32434. Epub 2023 Feb 17.
Fasiha Kanwal 1 2 3, Saira Khaderi 1, Amit G Singal 4, Jorge A Marrero 4, Nicole Loo 5, Sumeet K Asrani 6, Christopher I Amos 7, Aaron P Thrift 7, Xiangjun Gu 7, Michelle Luster 1, Abeer Al-Sarraj 1 2 3, Jing Ning 8, Hashem B El-Serag 1 2 3
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 16. | Radioembolization for Hepatocellular Carcinoma-Current Evidence and Patterns of Utilization |
| |
J Vasc Interv Radiol. 2023 Mar 29;S1051-0443(23)00254-3.doi: 10.1016/j.jvir.2023.03.020. Online ahead of print.
Hayley Briody 1, David Duong 2, Sern Wei Yeoh 3, Russell Hodgson 4, Tuck Leong Yong 4, Anthony Hannah 5, Michael J Lee 6, Sum Leong 7, Julian Maingard 8, Hamed Asadi 9, Hong Kuan Kok 10
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 22. | Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score |
| |
PLoS One. 2023 Feb 28;18(2):e0282309. doi: 10.1371/journal.pone.0282309. eCollection 2023.
Aaron P Thrift 1 2, Fasiha Kanwal 3 4, Yanhong Liu 1 2, Saira Khaderi 3, Amit G Singal 5, Jorge A Marrero 5, Nicole Loo 6, Sumeet K Asrani 7, Michelle Luster 3, Abeer Al-Sarraj 3 4, Jing Ning 8, Spiridon Tsavachidis 1, Xiangjun Gu 1, Christopher I Amos 1 2, Hashem B El-Serag 3 4
|
|
| |
|
|
| |
| 24. | Variations in Textbook Oncologic Outcomes After Curative-Intent Resection: Early Versus Intermediate Hepatocellular Carcinoma Based on Barcelona Clinic Liver Cancer Criteria and Child-Pugh Classification |
| |
Ann Surg Oncol. 2023 Feb;30(2):750-759. doi: 10.1245/s10434-022-12832-2.Epub 2022 Nov 20.
Zorays Moazzam 1, Laura Alaimo 1 2, Yutaka Endo 1, Henrique A Lima 1, Chanza F Shaikh 1, Francesca Ratti 3, Hugo P Marques 4, François Cauchy 5, Vincent Lam 6, George A Poultsides 7, Irinel Popescu 8, Sorin Alexandrescu 8, Guillaume Martel 9, Alfredo Guglielmi 2, Tom Hugh 10, Luca Aldrighetti 3, Itaru Endo 11, Timothy M Pawlik 12
|
|
| |
|
|
| |
|
|
| |
| 27. | Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study |
| |
Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):921-928.doi: 10.1007/s00259-022-06002-5. Epub 2022 Oct 25.
Jules Gregory 1 2 3 4, Lambros Tselikas 5, Caroline Allimant 6, Thierry de Baere 5, Irene Bargellini 7, Jon Bell 8, José Ignacio Bilbao 9, Antoine Bouvier 10, Julius Chapiro 11, Carlo Chiesa 12, Thomas Decaens 13, Alban Denys 14, Rafael Duran 14, Julien Edeline 15, Etienne Garin 16, Julien Ghelfi 13, Thomas Helmberger 17, Farah Irani 18, Marnix Lam 19, Robert Lewandowski 20, David Liu 21, Romaric Loffroy 22, David C Madoff 11, Charles Mastier 23, Riad Salem 20, Bruno Sangro 24, Daniel Sze 25, Valérie Vilgrain 26 27, Michael Vouche 28, Boris Guiu 6, Maxime Ronot 26 27
|
|
| |
|
|
| |
| 29. | LI-RADS: Looking Back, Looking Forward |
| |
Radiology. 2023 Apr;307(1):e222801. doi: 10.1148/radiol.222801. Epub 2023 Feb 28.
Victoria Chernyak 1, Kathryn J Fowler 1, Richard K G Do 1, Aya Kamaya 1, Yuko Kono 1, An Tang 1, Donald G Mitchell 1, Jeffrey Weinreb 1, Cynthia S Santillan 1, Claude B Sirlin 1
|
|
| |
| 30. | Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial |
| |
Clin Oncol. 2023 Mar 20;41(9):1747-1757.doi: 10.1200/JCO.22.00972. Epub 2022 Dec 13.
Thomas Yau 1, Vittorina Zagonel 2, Armando Santoro 3 4, Mirelis Acosta-Rivera 5, Su Pin Choo 6, Ana Matilla 7 8, Aiwu Ruth He 9, Antonio Cubillo Gracian 10 11, Anthony B El-Khoueiry 12, Bruno Sangro 13, Tarek E Eldawy 14, Jordi Bruix 15, Giovanni Luca Frassineti 16, Gina M Vaccaro 17, Marina Tschaika 18, Christian Scheffold 19, Petra Koopmans 18, Jaclyn Neely 18, Fabio Piscaglia 20
|
|
| |
| 31. | Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI |
| |
J Magn Reson Imaging. 2023 Mar 5. doi: 10.1002/jmri.28659. Online ahead of print.
Richa Patel 1, Anum Aslam 2, Neehar D Parikh 3, Benjamin Mervak 2, Eman Mubarak 2, Lily Higgins 2, Kayli Lala 2, Jack F Conner 4, Valerie Khaykin 5, Mustafa Bashir 6, Richard Kinh Gian Do 7, Lauren M B Burke 8, Elainea N Smith 9, Charles Y Kim 6, Kimberly L Shampain 2, Dawn Owen 10, Mishal Mendiratta-Lala 2
|
|
| |
|
|
| |
| 33. | Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin |
| |
Aliment Pharmacol Ther. 2023 Mar;57(6):600-609. doi: 10.1111/apt.17371.Epub 2023 Jan 10.
Rebecca W Zeng 1, Jie Ning Yong 1, Darren J H Tan 1, Clarissa E Fu 1, Wen Hui Lim 1, Jieling Xiao 1, Kai En Chan 1, Caitlyn Tan 1, Xin Lei Goh 1, Douglas Chee 2, Nicholas Syn 1, Eunice X Tan 1 2 3, Mark D Muthiah 1 2 3, Cheng Han Ng 1, Nobuharu Tamaki 4, Sung Won Lee 5 6, Beom Kyung Kim 7 8, Mindie H Nguyen 9, Rohit Loomba 10, Daniel Q Huang 1 2 3 10
|
|
| |
| 34. | Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada |
| |
Cancer Treat Rev. 2023 Apr;115:102526. doi: 10.1016/j.ctrv.2023.102526.Epub 2023 Mar 2.
Jason K Wong 1, Howard J Lim 2, Vincent C Tam 3, Kelly W Burak 4, Laura A Dawson 5, Prosanto Chaudhury 6, Robert J Abraham 7, Brandon M Meyers 8, Gonzalo Sapisochin 9, David Valenti 10, Setareh Samimi 11, Ravi Ramjeesingh 12, Amol Mujoomdar 13, Ilidio Martins 14, Elijah Dixon 15, Maja Segedi 16, David M Liu 17
|
|
| |
|
|
| |
|
|
| |
| 37. | Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma |
| |
Clin Cancer Res. 2023 Feb 16;29(4):754-763.doi: 10.1158/1078-0432.CCR-22-1983.
Xuyang Song 1, Robin Kate Kelley 2, Anis A Khan 1, Nathan Standifer 3, Diansong Zhou 4, KyoungSoo Lim 1, Rajesh Krishna 5, Lu Liu 6, Kun Wang 6, Patricia McCoon 7, Alejandra Negro 8, Philip He 9, Megan Gibbs 1, John F Kurland 10, Ghassan K Abou-Alfa 11 12
|
|
| |
| 38. | Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial |
| |
Dig Liver Dis. 2023 Apr;55(4):464-470.doi: 10.1016/j.dld.2023.01.161. Epub 2023 Feb 16.
Philippe Merle 1, Jean-Frédéric Blanc 2, Julien Edeline 3, Karine Le Malicot 4, Manon Allaire 5, Eric Assenat 6, Meriem Guarssifi 4, Mohamed Bouattour 7, Jean-Marie Péron 8, Pierre Laurent-Puig 9, Massimo Levrero 10, Charlotte Costentin 11, Boris Guiu 12, Harry Sokol 13, David Tougeron 14, Thomas Aparicio 15, Jean-Charles Nault 16, Jean-Marc Phelip 17
|
|
| |
|
|
| |
| 40. | Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population |
| |
Eur J Cancer. 2023 Feb;180:9-20.doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25.
Andrea Casadei-Gardini 1, Margherita Rimini 2, Toshifumi Tada 3, Goki Suda 4, Shigeo Shimose 5, Masatoshi Kudo 6, Jaekyung Cheon 7, Fabian Finkelmeier 8, Ho Yeong Lim 9, Lorenza Rimassa 10, José Presa 11, Gianluca Masi 12, Changhoon Yoo 13, Sara Lonardi 14, Francesco Tovoli 15, Takashi Kumada 16, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 7, Vera Himmelsbach 8, Tiziana Pressiani 17, Margarida Montes 11, Caterina Vivaldi 12, Caterina Soldà 14, Fabio Piscaglia 15, Atsushi Hiraoka 18, Takuya Sho 4, Takashi Niizeki 5, Naoshi Nishida 6, Christoph Steup 8, Massimo Iavarone 19, Giovanni Di Costanzo 20, Fabio Marra 21, Mario Scartozzi 22, Emiliano Tamburini 23, Giuseppe Cabibbo 24, Francesco Giuseppe Foschi 25, Marianna Silletta 26, Masashi Hirooka 27, Kazuya Kariyama 28, Joji Tani 29, Masanori Atsukawa 30, Koichi Takaguchi 31, Ei Itobayashi 32, Shinya Fukunishi 33, Kunihiko Tsuji 34, Toru Ishikawa 35, Kazuto Tajiri 36, Hironori Ochi 37, Satoshi Yasuda 38, Hidenori Toyoda 38, Chikara Ogawa 39, Takashi Nishimura 40, Takeshi Hatanaka 41, Satoru Kakizaki 42, Noritomo Shimada 43, Kazuhito Kawata 44, Fujimasa Tada 18, Hideko Ohama 18, Kazuhiro Nouso 28, Asahiro Morishita 29, Akemi Tsutsui 31, Takuya Nagano 31, Norio Itokawa 30, Tomomi Okubo 30, Taeang Arai 30, Michitaka Imai 35, Hisashi Kosaka 45, Atsushi Naganuma 46, Yohei Koizumi 28, Shinichiro Nakamura 3, Masaki Kaibori 45, Hiroko Iijima 40, Yoichi Hiasa 27, Valentina Burgio 2, Mara Persano 22, Angelo Della Corte 47, Francesca Ratti 48, Francesco De Cobelli
|
| |
| 42. | Predictors of early and late hepatocellular carcinoma recurrence |
| |
World J Gastroenterol. 2023 Feb 28;29(8):1243-1260. doi: 10.3748/wjg.v29.i8.1243.
Riccardo Nevola 1 2, Rachele Ruocco 1, Livio Criscuolo 1, Angela Villani 1, Maria Alfano 1, Domenico Beccia 1, Simona Imbriani 1, Ernesto Claar 3, Domenico Cozzolino 1, Ferdinando Carlo Sasso 1, Aldo Marrone 1, Luigi Elio Adinolfi 1, Luca Rinaldi 1
|
|
| |
|
|
| |
| 44. | Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery |
| |
AMA Surg. 2023 Feb 1;158(2):192-202. doi: 10.1001/jamasurg.2022.6697.
Simone Famularo 1 2, Matteo Donadon 1 2, Federica Cipriani 3, Federico Fazio 4, Francesco Ardito 5, Maurizio Iaria 6, Pasquale Perri 7, Simone Conci 8, Tommaso Dominioni 9, Quirino Lai 10, Giuliano La Barba 11, Stefan Patauner 12, Sarah Molfino 13, Paola Germani 14, Giuseppe Zimmitti 15, Enrico Pinotti 16, Matteo Zanello 17, Luca Fumagalli 18, Cecilia Ferrari 19, Maurizio Romano 20 21, Antonella Delvecchio 22, Maria Grazia Valsecchi 23, Adelmo Antonucci 24, Fabio Piscaglia 25, Fabio Farinati 26, Yoshikuni Kawaguchi 27, Kiyoshi Hasegawa 27, Riccardo Memeo 22, Giacomo Zanus 20 21, Guido Griseri 19, Marco Chiarelli 18, Elio Jovine 17, Mauro Zago 16 18, Moh'd Abu Hilal 15, Paola Tarchi 14, Gian Luca Baiocchi 13, Antonio Frena 12, Giorgio Ercolani 11, Massimo Rossi 10, Marcello Maestri 9, Andrea Ruzzenente 8, Gian Luca Grazi 7, Raffaele Dalla Valle 6, Fabrizio Romano 28, Felice Giuliante 5, Alessandro Ferrero 4, Luca Aldrighetti 3, Davide P Bernasconi 23, Guido Torzilli 1 2; HE.RC.O.LE.S. Group
|
|
| |
|
|
| |
|
|
| |
| 47. | Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies |
| |
Biomedicines. 2023 Feb 6;11(2):468. doi: 10.3390/biomedicines11020468.
Erica Vetrano 1, Luca Rinaldi 1, Andrea Mormone 1, Chiara Giorgione 1, Raffaele Galiero 1, Alfredo Caturano 1, Riccardo Nevola 1, Raffaele Marfella 1, Ferdinando Carlo Sasso 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 51. | HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma |
| |
Hepatology. 2023 Mar 1;77(3):774-788. doi: 10.1002/hep.32692. Epub 2023 Feb 17.
Na Sun 1 2, Ceng Zhang 1 3, Yi-Te Lee 1, Benjamin V Tran 4, Jing Wang 1, Hyoyong Kim 1, Junseok Lee 1, Ryan Y Zhang 1, Jasmine J Wang 1 5, Junhui Hu 6, Zhicheng Zhang 6, Manaf S Alsudaney 7, Kuan-Chu Hou 1, Hubert Tang 1, Tiffany X Zhang 1, Icy Y Liang 1, Ziang Zhou 1, Mengxiang Chen 1, Angela Hsiao-Jiun Yeh 8, Wenyuan Li 9, Xianghong Jasmine Zhou 9, Helena R Chang 4, Steven-Huy B Han 8, Saeed Sadeghi 8, Richard S Finn 8, Sammy Saab 8, Ronald W Busuttil 4, Mazen Noureddin 7 10, Walid S Ayoub 7 10, Alexander Kuo 7 10, Vinay Sundaram 7 10, Buraq Al-Ghaieb 7 10, Juvelyn Palomique 7, Kambiz Kosari 7, Irene K Kim 7, Tsuyoshi Todo 7, Nicholas N Nissen 7, Maria Lauda Tomasi 10, Sungyong You 11, Edwin M Posadas 5, James X Wu 4, Madhuri Wadehra 9, Myung-Shin Sim 12, Yunfeng Li 9, Hanlin L Wang 9, Samuel W French 9, Shelly C Lu 10 13, Lily Wu 6, Renjun Pei 2, Li Liang 14 15, Ju Dong Yang 7 10 13, Vatche G Agopian 4 16, Hsian-Rong Tseng 1 16, Yazhen Zhu 1 9 16
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 59. | Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database |
| |
Gut. 2023 Jan;72(1):141-152. doi: 10.1136/gutjnl-2021-324915. Epub 2021 Dec 21.
Alessandro Vitale # 1, Gianluca Svegliati-Baroni # 2 3, Alessio Ortolani 4, Monica Cucco 5 6, Giulio V Dalla Riva 7, Edoardo G Giannini 8, Fabio Piscaglia 9, Gianludovico Rapaccini 10, Mariella Di Marco 11, Eugenio Caturelli 12, Marco Zoli 13, Rodolfo Sacco 14, Giuseppe Cabibbo 15, Fabio Marra 16, Andrea Mega 17, Filomena Morisco 18, Antonio Gasbarrini 19, Francesco Giuseppe Foschi 20, Gabriele Missale 21, Alberto Masotto 22, Gerardo Nardone 23, Giovanni Raimondo 24, Francesco Azzaroli 25, Gianpaolo Vidili 26, Filippo Oliveri 27, Filippo Pelizzaro 1, Rafael Ramirez Morales 1, Umberto Cillo 1, Franco Trevisani 28, Luca Miele 29 30, Giulio Marchesini 31, Fabio Farinati 1; Italian Liver Cancer (ITA.LI.CA) group
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 67. | FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? |
| |
Int J Mol Sci. 2023 Jan 31;24(3):2685. doi: 10.3390/ijms24032685.
Iason Psilopatis 1, Christos Damaskos 2 3, Anna Garmpi 4, Panagiotis Sarantis 5, Evangelos Koustas 5, Efstathios A Antoniou 3 6, Dimitrios Dimitroulis 6, Gregory Kouraklis 6, Michail V Karamouzis 5, Kleio Vrettou 7, Georgios Marinos 8, Konstantinos Kontzoglou 3 6, Nikolaos Garmpis 3 6
|
|
| |
|
|
| |
| 69. | An Open-Access, Interactive Decision-Support Tool to Facilitate Guideline-Driven Care for Hepatocellular Carcinoma |
| |
Gastroenterology Res. 2022 Dec;15(6):297-307. doi: 10.14740/gr1573.Epub 2022 Dec 1.
Robert J Wong 1, Channa Jayasekera 2, Patricia Jones 3, Fasiha Kanwal 4, Amit G Singal 5, Aijaz Ahmed 6, Robert Taglienti 7, Zobair Younossi 8, Laura Kulik 9, Neil Mehta 10
|
|
| |
|
|
| |
|
|
| |
| 72. | Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2 |
| |
Oncologist. 2022 Dec 9;27(12):e938-e948. doi: 10.1093/oncolo/oyac183.
Richard S Finn 1, Thomas Yau 2, Chih-Hung Hsu 3, Enrico N De Toni 4, Lipika Goyal 5, Peter R Galle 6, ShuKui Qin 7, Sujata Rao 8, Fangfang Sun 8, Chunxiao Wang 8, Ryan C Widau 8, Andrew X Zhu 9 10
|
|
| |
|
|
| |
|
|
| |
| 75. | A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC |
| |
Liver Int. 2022 Dec;42(12):2843-2854. doi: 10.1111/liv.15458. Epub 2022 Oct 26.
Edouard Larrey 1, Bertille Campion 1, Manon Evain 1, Philippe Sultanik 1, Lorraine Blaise 2, Héloïse Giudicelli 1, Mathilde Wagner 3, Philippe Cluzel 4, Marika Rudler 1 5, Nathalie Ganne-Carrié 2 6, Dominique Thabut 1 5, Manon Allaire 1 6
|
|
| |
|
|
| |
| 77. | Surgical approach to microwave and radiofrequency liver ablation for hepatocellular carcinoma and colorectal liver metastases less than 5 cm: a systematic review and meta-analysis |
| |
Surg Endosc. 2022 Dec 21. doi: 10.1007/s00464-022-09815-5.Online ahead of print.
Moustafa Abdalla 1, Amelia T Collings 2, Rebecca Dirks 2, Edwin Onkendi 3, Daniel Nelson 4, Ahmad Ozair 5, Emily Miraflor 6, Faique Rahman 7, Jake Whiteside 2, Mihir M Shah 8, Subhashini Ayloo 9, Ahmed Abou-Setta 10, Iswanto Sucandy 11, Ali Kchaou 12, Samuel Douglas 13, Patricio Polanco 14, Timothy Vreeland 15, Joseph Buell 16, Mohammed T Ansari 17, Aurora D Pryor 18, Bethany J Slater 19, Ziad Awad 20, William Richardson 21, Adnan Alseidi 22, D Rohan Jeyarajah 23, Eugene Ceppa 24
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 84. | Pathogenesis to management of hepatocellular carcinoma |
| |
Genes Cancer. 2022 Dec 13;13:72-87. doi: 10.18632/genesandcancer.226.eCollection 2022.
Ben L Da 1, Kelly I Suchman 2, Lawrence Lau 3, Atoosa Rabiee 4, Aiwu Ruth He 5, Kirti Shetty 6, Herbert Yu 7, Linda L Wong 8, Richard L Amdur 9, James M Crawford 10, Sharon S Fox 10, Gregory M Grimaldi 11, Priya K Shah 11, Jonathan Weinstein 12, David Bernstein 1, Sanjaya K Satapathy 1, Nyasha Chambwe 13, Xiyan Xiang 14, Lopa Mishra 14
|
|
| |
|
|
| |
| 86. | Safety and Efficacy of 166Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study |
| |
J Nucl Med. 2022 Dec;63(12):1891-1898. doi: 10.2967/jnumed.122.263823.Epub 2022 May 19.
Margot T M Reinders 1, Karel J van Erpecum 2, Maarten L J Smits 3, Arthur J A T Braat 3, Joep de Bruijne 2, Rutger Bruijnen 3, Dave Sprengers 4, Robert A de Man 4, Erik Vegt 5, Jan N M IJzermans 6, Adriaan Moelker 5, Marnix G E H Lam 1
|
|
| |
| 87. | Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance |
| |
Clin Gastroenterol Hepatol. 2022 Dec;20(12):2818-2825.e1.doi: 10.1016/j.cgh.2021.12.014. Epub 2021 Dec 10.
Amit G Singal 1, Sarah Reddy 2, Himani Radadiya Aka Patel 3, Deyaun Villarreal 3, Aisha Khan 4, Yan Liu 4, Vanessa Cerda 3, Nicole E Rich 2, Caitlin C Murphy 3, Jasmin A Tiro 3, Jennifer R Kramer 5, Ruben Hernaez 5
|
|
| |
| 88. | SIRT in 2025 |
| |
Cardiovasc Intervent Radiol. 2022 Nov;45(11):1622-1633.doi: 10.1007/s00270-022-03228-6. Epub 2022 Aug 8.
Francesca Romana Ponziani # 1, Francesco Santopaolo # 1, Alessandro Posa 2, Maurizio Pompili 1 3, Alessandro Tanzilli 2, Marta Maestri 1, Maria Pallozzi 1, Francesca Ibba 1, Riccardo Manfredi 2 3, Antonio Gasbarrini # 1 3, Roberto Iezzi # 4 5
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 94. | Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review |
| |
Int J Mol Sci. 2022 Nov 15;23(22):14117. doi: 10.3390/ijms232214117.
Christos Damaskos 1 2, Nikolaos Garmpis 2 3, Dimitrios Dimitroulis 3, Anna Garmpi 4, Iason Psilopatis 5, Panagiotis Sarantis 6, Evangelos Koustas 6, Prodromos Kanavidis 7, Dionysios Prevezanos 1, Gregory Kouraklis 7, Michail V Karamouzis 6, Georgios Marinos 8, Konstantinos Kontzoglou 2 3, Efstathios A Antoniou 2 3
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 99. | Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360) |
| |
Curr Oncol. 2022 Nov 16;29(11):8802-8813. doi: 10.3390/curroncol29110692.
Tiziana Comito 1, Mauro Loi 2, Ciro Franzese 1 3, Elena Clerici 1, Davide Franceschini 1, Marco Badalamenti 1, Maria Ausilia Teriaca 1, Lorenza Rimassa 3 4, Vittorio Pedicini 5, Dario Poretti 5, Luigi Alessandro Solbiati 3 5, Guido Torzilli 3 6, Roberto Ceriani 7, Ana Lleo 3 7, Alessio Aghemo 3 7, Armando Santoro 3 4, Marta Scorsetti 1 3
|
|
| |
| 100. | Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis |
| |
ESMO Open. 2022 Oct 5;7(6):100591. doi: 10.1016/j.esmoop.2022.100591. Online ahead of print.
M Rimini 1, L Rimassa 2, K Ueshima 3, V Burgio 1, S Shigeo 4, T Tada 5, G Suda 6, C Yoo 7, J Cheon 8, D J Pinato 9, S Lonardi 10, M Scartozzi 11, M Iavarone 12, G G Di Costanzo 13, F Marra 14, C Soldà 15, E Tamburini 16, F Piscaglia 17, G Masi 18, G Cabibbo 19, F G Foschi 20, M Silletta 21, T Pressiani 22, N Nishida 3, H Iwamoto 4, N Sakamoto 6, B-Y Ryoo 7, H J Chon 8, F Claudia 9, T Niizeki 4, T Sho 6, B Kang 8, A D'Alessio 9, T Kumada 23, A Hiraoka 24, M Hirooka 25, K Kariyama 26, J Tani 27, M Atsukawa 28, K Takaguchi 29, E Itobayashi 30, S Fukunishi 31, K Tsuji 32, T Ishikawa 33, K Tajiri 34, H Ochi 35, S Yasuda 36, H Toyoda 36, C Ogawa 37, T Nishimur 38, T Hatanaka 39, S Kakizaki 40, N Shimada 41, K Kawata 42, T Tanaka 24, H Ohama 31, K Nouso 26, A Morishita 27, A Tsutsui 29, T Nagano 29, N Itokawa 28, T Okubo 28, T Arai 28, M Imai 33, A Naganuma 43, Y Koizumi 25, S Nakamura 5, K Joko 35, H Iijima 38, Y Hiasa 25, F Pedica 44, F De Cobelli 45, F Ratti 46, L Alrighetti 46, M Kudo 3, S Cascinu 47, A Casadei-Gardini 48
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 104. | Artificial Intelligence in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review |
| |
J Clin Med. 2022 Oct 28;11(21):6368. doi: 10.3390/jcm11216368.
Alessandro Martinino 1, Mohammad Aloulou 2, Surobhi Chatterjee 3, Juan Pablo Scarano Pereira 4, Saurabh Singhal 5, Tapan Patel 6, Thomas Paul-Emile Kirchgesner 7, Salvatore Agnes 8, Salvatore Annunziata 9, Giorgio Treglia 10 11 12, Francesco Giovinazzo 8
|
|
| |
|
|
| |
|
|
| |
| 107. | Hepatocellular Carcinoma, Alpha Fetoprotein, and Liver Allocation for Transplantation: Past, Present and Future |
| |
Curr Oncol. 2022 Oct 8;29(10):7537-7551. doi: 10.3390/curroncol29100593.
Brianna Ruch 1, Josiah Wagler 1, Kayla Kumm 1, Chi Zhang 2 3, Nitin N Katariya 1, Mauricio Garcia-Saenz-de-Sicilia 4, Emmanouil Giorgakis 5, Amit K Mathur 1
|
|
| |
| 108. | Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial |
| |
J Gastroenterol Hepatol. 2015 Mar;30(3):559-65.doi: 10.1111/jgh.12791.
Giovan Giuseppe Di Costanzo 1, Raffaella Tortora, Giuseppe D'Adamo, Massimo De Luca, Filippo Lampasi, Luigi Addario, Alfonso Galeota Lanza, Francesco Paolo Picciotto, Maria Teresa Tartaglione, Gabriella Cordone, Michele Imparato, Silvana Mattera, Claudio Maurizio Pacella
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 113. | Downstaging Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis on Intention-to-Treat Outcomes |
| |
Cancers (Basel). 2022 Oct 18;14(20):5102. doi: 10.3390/cancers14205102.
Marcello Di Martino 1, Alessandro Vitale 2, Daniele Ferraro 1, Marilisa Maniscalco 1, Donatella Pisaniello 1, Giuseppe Arenga 1, Federica Falaschi 1, Alfonso Terrone 1, Alessandro Iacomino 1 2, Alfonso Galeota Lanza 3, Ciro Esposito 4, Umberto Cillo 2, Giovanni Vennarecci 1
|
|
| |
| 114. | Securing Wider EU Commitment to the Elimination of HCV |
| |
Liver Int. 2022 Oct 5. doi: 10.1111/liv.15446. Online ahead of print.
Heiner Wedemeyer 1, Tammo L Tergast 1, Jeffrey V Lazarus 2, Homie Razavi 3, Kostas Bakoyannis 4, Ricardo Baptista-Leite 5 6, Marco Bartoli 7, Philip Bruggmann 8, Cristian-Silviu Busoi 9, Maria Buti 10, Manuel Carballo 11, Laurent Castera 12, Massimo Colombo 13, Rodrigo Sousa Coutinho 14, Yuval Dadon 15, Gamal Esmat 16, Rafael Esteban 10, Joan Colom Farran 17, Mark Gillyon-Powell 18, David Goldberg 19, Sharon Hutchinson 20, Harry L A Janssen 21, George Kalamitsis 22, Loreta A Kondili 23, John S Lambert 24, Rui Tato Marinho 25, Mojca Maticic 26 27, Aldo Patricello 9, Markus Peck-Radosavljevic 28, Stanislas Pol 29, Mario Poljak 30, Cora Pop 31, Tomislov Sokol 9, Vana Sypsa 32, Nurdan Tözün 33, Zobair Younossi 34, Alessio Aghemo 35, George V Papatheodoridis 36, Angelos Hatzakis 32
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 123. | Early derangement of INR predicts liver failure after liver resection for hepatocellular carcinoma |
| |
Surgeon. 2022 Oct;20(5):e288-e295. doi: 10.1016/j.surge.2022.01.002.Epub 2022 Feb 7.
A N S Silva 1, M Greensmith 2, R K Praseedom 2, A Jah 2, E L Huguet 2, S J F Harper 2, S S Liau 2, B Basu 3, G J Alexander 4, R Brais 5, T C See 6, M Hoare 7, P Gibbs 2, A Balakrishnan 8
|
|
| |
|
|
| |
|
|
| |
| 126. | Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature |
| |
Hepatol Commun. 2022 Sep;6(9):2581-2593. doi: 10.1002/hep4.1991. Epub 2022 Jun 16.
Myung-Ho Kim 1, Mi-Young Kim 1 2 3, Shadi Salloum 1, Tongqi Qian 4, Lai Ping Wong 5 6, Min Xu 1, Yoojin Lee 1, Stuti G Shroff 7, Ruslan I Sadreyev 5 7, Kathleen E Corey 1, Thomas F Baumert 8 9, Yujin Hoshida 4, Raymond T Chung 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 132. | Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study |
| |
Cancer. 2022 Jul 15;128(14):2786-2795. doi: 10.1002/cncr.34256. Epub 2022 May 13.
Scott S Short 1, Zachary J Kastenberg 1, Guo Wei 1, Alex Bondoc 2, Roshni Dasgupta 2, Greg M Tiao 2, Erin Watters 2, Todd E Heaton 3, Dimitra Lotakis 3, Michael P La Quaglia 3, Andrew J Murphy 4, Andrew M Davidoff 4, Sara A Mansfield 4, Max R Langham 4, Timothy B Lautz 5, Riccardo A Superina 5, Katherine C Ott 5, Marcus M Malek 6, Katrina M Morgan 6, Eugene S Kim 7, Abigail Zamora 7, Danny Lascano 7, Jonathan Roach 8, Joseph T Murphy 9, David H Rothstein 10, Sanjeev A Vasudevan 11, Richard Whitlock 11, Dave R Lal 12, Brian Hallis 12, Andreana Bütter 13, Reto M Baertschiger 14, Eveline Lapidus-Krol 14, Juan Putra 15, Elisabeth R Tracy 16, Jennifer H Aldrink 17, Jordan Apfeld 17, Hau D Le 18, Keon Y Park 18, Barrie S Rich 19, Richard D Glick 19, Elizabeth A Fialkowski 20, Alan F Utria 20, Rebecka L Meyers 1, Kimberly J Riehle 10
|
|
| |
|
|
| |
| 134. | Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies |
| |
Clin Cancer Res. 2022 Aug 15;28(16):3443-3451.doi: 10.1158/1078-0432.CCR-21-3135.
Masatoshi Kudo # 1, Robert Montal # 2 3, Richard S Finn 4, Florian Castet 3, Kazuomi Ueshima 1, Naoshi Nishida 1, Philipp K Haber 5, Youyou Hu 6, Yasutaka Chiba 7, Myron Schwartz 5, Tim Meyer 8 9, Riccardo Lencioni 10 11, Josep M Llovet 3 5 12
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 144. | Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial |
| |
J Cancer Res Clin Oncol. 2022 Sep;148(9):2487-2496.doi: 10.1007/s00432-021-03803-3. Epub 2021 Sep 20.
Osman Öcal # 1, Daniel Rössler # 2, Antonio Gasbarrini 3, Thomas Berg 4, Heinz-Josef Klümpen 5, Irene Bargellini 6, Bora Peynircioglu 7, Otto van Delden 8, Christian Schulz 2, Kerstin Schütte 9 10, Roberto Iezzi 11, Maciej Pech 12, Peter Malfertheiner 2, Bruno Sangro 13, Jens Ricke 1, Max Seidensticker 14
|
|
| |
| 145. | Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis |
| |
Clin Gastroenterol Hepatol. 2022 Aug 5;S1542-3565(22)00727-3.doi: 10.1016/j.cgh.2022.06.032. Online ahead of print.
Daniel Q Huang 1, Darren J H Tan 2, Cheng Han Ng 2, Maral Amangurbanova 3, Nancy Sutter 3, Phoebe Wen Lin Tay 2, Wen Hui Lim 2, Jie Ning Yong 2, Ansel Tang 2, Nicholas Syn 2, Mark D Muthiah 4, Eunice X X Tan 4, Shravan Dave 3, Benjamin Tay 5, Abdul M Majzoub 6, Danielle Gerberi 7, Beom Kyung Kim 8, Rohit Loomba 9
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 149. | Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival |
| |
Dig Liver Dis. 2022 Jul;54(7):927-936. doi: 10.1016/j.dld.2021.08.025. Epub 2021 Sep 25.
Filippo Pelizzaro 1, Giulia Peserico 2, Marco D'Elia 1, Nora Cazzagon 1, Francesco Paolo Russo 3, Alessandro Vitale 4, Edoardo G Giannini 5, Manuela Piccinnu 6, Gian Ludovico Rapaccini 7, Maria Di Marco 8, Eugenio Caturelli 9, Marco Zoli 10, Rodolfo Sacco 11, Giuseppe Cabibbo 12, Fabio Marra 13, Andrea Mega 14, Filomena Morisco 15, Antonio Gasbarrini 16, Gianluca Svegliati-Baroni 17, Francesco Giuseppe Foschi 18, Andrea Olivani 19, Alberto Masotto 20, Gerardo Nardone 21, Giovanni Raimondo 22, Francesco Azzaroli 23, Gianpaolo Vidili 24, Filippo Oliveri 25, Franco Trevisani 26, Fabio Farinati 27, Italian Liver Cancer (ITA.LI.CA) Study Group
|
|
| |
| 150. | Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation |
| |
JCI Insight. 2022 Jul 8;7(13):e159254. doi: 10.1172/jci.insight.159254.
Emilie Crouchet 1, Shen Li 2, Mozhdeh Sojoodi 2, Simonetta Bandiera 1, Naoto Fujiwara 3, Hussein El Saghire 1, Shijia Zhu 3, Tongqi Qian 3, Fahmida Akter Rasha 3, Fabio Del Zompo 1, Stephen C Barrett 2, Eugénie Schaeffer 1, Marine A Oudot 1, Clara Ponsolles 1, Sarah C Durand 1, Sarani Ghoshal 2, Gunisha Arora 2, Fabio Giannone 1 4 5, Raymond T Chung 6, Nevena Slovic 1, Nicolaas Van Renne 1, Emanuele Felli 1 4 5, Patrick Pessaux 1 4 5, Joachim Lupberger 1, Nathalie Pochet 7 8 9, Catherine Schuster 1, Kenneth K Tanabe 2, Yujin Hoshida 3, Bryan C Fuchs 2, Thomas F Baumert 1 4
|
|
| |
| 151. | Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis |
| |
Transpl Int. 2022 Jul 5;35:10175. doi: 10.3389/ti.2022.10175. eCollection 2022.
Ryan Lamm 1, Peter J Altshuler 1, Keyur Patel 1, Osama Shaheen 1, Angel Paulo Amante 1, Jesse Civan 2, Warren Maley 1, Adam Frank 1, Carlo Ramirez 1, Jaime Glorioso 1, Ashesh Shah 1, Hien Dang 1, Adam S Bodzin 1
|
|
| |
|
|
| |
| 153. | Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment |
| |
Nat Commun. 2022 Jul 8;13(1):3964. doi: 10.1038/s41467-022-31312-5.
Kai Markus Schneider # 1 2, Antje Mohs # 1, Wenfang Gui 1, Eric J C Galvez 3, Lena Susanna Candels 1, Lisa Hoenicke 3, Uthayakumar Muthukumarasamy 3, Christian H Holland 4 5, Carsten Elfers 1, Konrad Kilic 1, Carolin Victoria Schneider 1 6, Robert Schierwagen 7 8, Pavel Strnad 1, Theresa H Wirtz 1, Hanns-Ulrich Marschall 9, Eicke Latz 10 11 12, Benjamin Lelouvier 13, Julio Saez-Rodriguez 4 5, Willem de Vos 14 15, Till Strowig 3, Jonel Trebicka 7 8, Christian Trautwein 16
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 158. | Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases |
| |
Hepatology. 2022 Jul;76(1):251-274. doi: 10.1002/hep.32313. Epub 2022 Jan 22.
Marina Serper 1 2 3, Neehar D Parikh 4, Grace Thiele 1, Nadia Ovchinsky 5, Shivang Mehta 6, Alexander Kuo 7, Chanda Ho 8, Fasiha Kanwal 9 10 11, Michael Volk 12, Sumeet K Asrani 13, Marwan S Ghabril 14, John R Lake 15, Raphael B Merriman 16, Timothy R Morgan 17, Elliot B Tapper 4 18
|
|
| |
|
|
| |
| 160. | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial |
| |
Lancet Oncol. 2022 Aug;23(8):995-1008.doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.
Robin Kate Kelley 1, Lorenza Rimassa 2, Ann-Lii Cheng 3, Ahmed Kaseb 4, Shukui Qin 5, Andrew X Zhu 6, Stephen L Chan 7, Tamar Melkadze 8, Wattana Sukeepaisarnjaroen 9, Valery Breder 10, Gontran Verset 11, Edward Gane 12, Ivan Borbath 13, Jose David Gomez Rangel 14, Baek-Yeol Ryoo 15, Tamta Makharadze 16, Philippe Merle 17, Fawzi Benzaghou 18, Kamalika Banerjee 19, Saswati Hazra 19, Jonathan Fawcett 19, Thomas Yau 20
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 173. | HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis |
| |
J Hepatol. 2022 Jul;77(1):128-139. doi: 10.1016/j.jhep.2022.01.023.Epub 2022 Feb 6.
Amit G Singal 1, Emily Zhang 2, Manasa Narasimman 2, Nicole E Rich 2, Akbar K Waljee 3, Yujin Hoshida 2, Ju Dong Yang 4, Maria Reig 5, Giuseppe Cabibbo 6, Pierre Nahon 7, Neehar D Parikh 3, Jorge A Marrero 8
|
|
| |
|
|
| |
| 175. | Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial |
| |
Clin Cancer Res. 2022 Jun 13;28(12):2547-2554.doi: 10.1158/1078-0432.CCR-21-3807
Gontran Verset 1, Ivan Borbath 2, Mark Karwal 3, Chris Verslype 4, Hans Van Vlierberghe 5, Adel Kardosh 6, Vittorina Zagonel 7, Per Stal 8, Debashis Sarker 9, Daniel H Palmer 10, Arndt Vogel 11, Julien Edeline 12, Stephane Cattan 13, Masatoshi Kudo 14, Ann-Lii Cheng 15, Sadahisa Ogasawara 16, Bruno Daniele 17, Stephen L Chan 18, Jennifer J Knox 19, Shukui Qin 20, Abby B Siegel 21, Michael Chisamore 21, Ken Hatogai 21, Anran Wang 21, Richard S Finn # 22, Andrew X Zhu # 23 24
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 187. | Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials |
| |
Clin Cancer Res. 2022 Jun 1;28(11):2297-2305.doi: 10.1158/1078-0432.CCR-21-4000.
Josep M Llovet 1 2 3, Amit G Singal 4, Augusto Villanueva 1, Richard S Finn 5, Masatoshi Kudo 6, Peter R Galle 7, Masafumi Ikeda 8, Sophie Callies 9, Louise M McGrath 9, Chunxiao Wang 9, Paolo Abada 9, Ryan C Widau 9, Elena Gonzalez-Gugel 9, Andrew X Zhu 10 11
|
|
| |
|
| | | | | | |
